DK1308168T3 - Nye lægemidler mod cancer - Google Patents

Nye lægemidler mod cancer

Info

Publication number: DK1308168T3
Authority: DK; Denmark
Prior art keywords: cancer drugs; new anti; medicament; pharmaceutically acceptable; acceptable salt
Prior art date: 2000-07-28

Application number

DK01954360T

Other languages

English (en)

Inventor

Toshihiro Noguchi

Akemi Baba

Mitsuharu Hanada

Original Assignee

Dainippon Sumitomo Pharma Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-07-28

Filing date

2001-07-26

Publication date

2008-07-28

2001-07-26 Application filed by Dainippon Sumitomo Pharma Co filed Critical Dainippon Sumitomo Pharma Co

2008-07-28 Application granted granted Critical

2008-07-28 Publication of DK1308168T3 publication Critical patent/DK1308168T3/da

Links

239000002246 antineoplastic agent Substances 0.000 title 1
229940041181 antineoplastic drug Drugs 0.000 title 1
206010028980 Neoplasm Diseases 0.000 abstract 1
239000004480 active ingredient Substances 0.000 abstract 1
VJZITPJGSQKZMX-XDPRQOKASA-N amrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC=C4C(=O)C=3C(O)=C21)(N)C(=O)C)[C@H]1C[C@H](O)[C@H](O)CO1 VJZITPJGSQKZMX-XDPRQOKASA-N 0.000 abstract 1
229960002550 amrubicin Drugs 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
238000002648 combination therapy Methods 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Oncology (AREA)
Microbiology (AREA)
Mycology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Biophysics (AREA)
Biomedical Technology (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

DK01954360T 2000-07-28 2001-07-26 Nye lægemidler mod cancer DK1308168T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2000228239		2000-07-28
PCT/JP2001/006467 WO2002009754A1 (fr)	2000-07-28	2001-07-26	Nouveaux remedes contre le cancer

Publications (1)

Publication Number	Publication Date
DK1308168T3 true DK1308168T3 (da)	2008-07-28

Family

ID=18721568

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK01954360T DK1308168T3 (da)	2000-07-28	2001-07-26	Nye lægemidler mod cancer

Country Status (13)

Country	Link
US (3)	US7449181B2 (da)
EP (1)	EP1308168B1 (da)
JP (1)	JP5117660B2 (da)
KR (1)	KR20030019623A (da)
CN (2)	CN101732333B (da)
AT (1)	ATE397458T1 (da)
AU (1)	AU2001276689A1 (da)
CA (1)	CA2417255C (da)
DE (1)	DE60134324D1 (da)
DK (1)	DK1308168T3 (da)
ES (1)	ES2307633T3 (da)
TW (1)	TWI317285B (da)
WO (1)	WO2002009754A1 (da)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7625859B1 (en) *	2000-02-16	2009-12-01	Oregon Health & Science University	HER-2 binding antagonists
US7393823B1 (en)	1999-01-20	2008-07-01	Oregon Health And Science University	HER-2 binding antagonists
KR20150032891A (ko) *	2000-05-19	2015-03-30	제넨테크, 인크.	ＥｒｂＢ 길항제에 의한 암 치료요법에 대한 효과적인 반응의 가능성을 개선시키기 위한 유전자 검출 분석
KR100978705B1 (ko) *	2002-03-18	2010-08-30	다이닛본 스미토모 세이야꾸 가부시끼가이샤	폐암 치료
FR2844455B1 (fr) *	2002-09-13	2007-12-14	Lab Francais Du Fractionnement	Traitement des pathologies echappant a la reponse immune par des anticorps optimises
CA2583230A1 (en) *	2004-10-05	2006-04-20	Oregon Health And Science University	Compositions and methods for treating disease
CN100464783C (zh) *	2004-11-22	2009-03-04	山东蓝金生物工程有限公司	一种含抗肿瘤抗生素的抗癌药物组合物
AR050418A1 (es)	2005-01-21	2006-10-25	Genentech Inc	Dosificacion fija de anticuerpos her
CN101163503B (zh) *	2005-02-23	2013-05-08	健泰科生物技术公司	使用her二聚化抑制剂在癌症患者中延长病情进展前时间或存活
US20060204505A1 (en) *	2005-03-08	2006-09-14	Sliwkowski Mark X	Methods for identifying tumors responsive to treatment with HER dimerization inhibitors (HDIs)
JP2006316040A (ja)	2005-05-13	2006-11-24	Genentech Inc	Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法
PE20090681A1 (es)	2007-03-02	2009-06-10	Genentech Inc	Prediccion de respuesta a un inhibidor her
US9551033B2 (en)	2007-06-08	2017-01-24	Genentech, Inc.	Gene expression markers of tumor resistance to HER2 inhibitor treatment
SI2171090T1 (sl)	2007-06-08	2013-07-31	Genentech, Inc.	Markerji genskega izraĹľanja tumorske odpornosti na HER2 inhibitorsko zdravljenje
BRPI0812682A2 (pt)	2008-06-16	2010-06-22	Genentech Inc	tratamento de cáncer de mama metastático
MX2011004467A (es)	2008-10-31	2011-07-28	Biogen Idec Inc	Moleculas de objetivo light y usos de las mismas.
CA2755640C (en)	2009-03-20	2018-05-22	Genentech, Inc.	Bispecific antibody with a single antigen-binding domain specific for both her3 and egfr
JP5705836B2 (ja)	2009-05-29	2015-04-22	エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト	Ｈｅｒ２を発現する胃癌患者のｈｅｒ２シグナル伝達のためのモジュレーター
US9556249B2 (en)	2010-02-18	2017-01-31	Genentech, Inc.	Neuregulin antagonists and use thereof in treating cancer
WO2011146568A1 (en)	2010-05-19	2011-11-24	Genentech, Inc.	Predicting response to a her inhibitor
US20130245233A1 (en)	2010-11-24	2013-09-19	Ming Lei	Multispecific Molecules
WO2012085111A1 (en)	2010-12-23	2012-06-28	F. Hoffmann-La Roche Ag	Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
CA2842375A1 (en)	2011-08-17	2013-02-21	Erica Jackson	Neuregulin antibodies and uses thereof
US9327023B2 (en)	2011-10-25	2016-05-03	The Regents Of The University Of Michigan	HER2 targeting agent treatment in non-HER2-amplified cancers having HER2 expressing cancer stem cells
AU2012346540C1 (en)	2011-11-30	2019-07-04	Genentech, Inc.	ErbB3 mutations in cancer
WO2013083810A1 (en)	2011-12-09	2013-06-13	F. Hoffmann-La Roche Ag	Identification of non-responders to her2 inhibitors
MX2014011500A (es)	2012-03-27	2014-12-05	Genentech Inc	Diagnosticos y tratamientos relacionados a inhibidores her3.
CN104813168B (zh)	2012-11-30	2017-10-20	霍夫曼-拉罗奇有限公司	需要pd‑l1抑制剂综合疗法的患者的鉴定
WO2017194554A1 (en)	2016-05-10	2017-11-16	Inserm (Institut National De La Sante Et De La Recherche Medicale)	Combinations therapies for the treatment of cancer
CN107349426B (zh) *	2017-07-12	2018-03-23	马骥	阿司匹林与曲妥珠单抗联合或协同在肿瘤治疗中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS6075473A (ja)	1983-09-30	1985-04-27	Sumitomo Chem Co Ltd	アミノナフタセン誘導体
US5185432A (en) *	1986-02-26	1993-02-09	Oncogen	Monoclonal antibodies and antigen for human non-small cell lung carcinoma and other certain human carcinomas
WO1989006692A1 (en) *	1988-01-12	1989-07-27	Genentech, Inc.	Method of treating tumor cells by inhibiting growth factor receptor function
US5077220A (en) *	1988-08-26	1991-12-31	John Muir Cancer & Aging Institute	Monoclonal antibody specific to a novel glycoprotein antigen on human carcinoma cells
JPH035397A (ja)	1989-05-31	1991-01-11	Toshiba Corp	酸化物結晶薄膜の気相成長方法
JP3005397B2 (ja)	1993-09-06	2000-01-31	関西日本電気ソフトウェア株式会社	デッドロック多発自動回避方式
US5686278A (en) *	1994-03-25	1997-11-11	Indiana University Foundation	Methods for enhanced retrovirus-mediated gene transfer
CN1164238A (zh) *	1994-09-12	1997-11-05	国际生物免疫有限公司	抗人结肠癌相关抗原的单克隆抗体及其应用
NZ330868A (en) *	1996-02-13	2000-01-28	Zeneca Ltd	4-phenoxy, phenylthio or phenylamino substituted quinazoline derivatives ane medicaments useful as VEGF inhibitors
CN1082187C (zh) *	1996-11-26	2002-04-03	北京市肿瘤防治研究所	一种检测雌激素受体水平的生物试剂及免疫组化方法
KR100565883B1 (ko) *	1997-01-22	2006-03-31	보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템	응고 및 종양 치료용 조직 인자 방법 및 조성물
US20030068318A1 (en) *	2001-09-28	2003-04-10	O'brien Timothy	Treatment of uterine serous papillary cancer

2001
- 2001-07-24 TW TW90118039A patent/TWI317285B/zh not_active IP Right Cessation
- 2001-07-26 AU AU2001276689A patent/AU2001276689A1/en not_active Abandoned
- 2001-07-26 US US10/333,978 patent/US7449181B2/en not_active Expired - Fee Related
- 2001-07-26 KR KR10-2003-7001194A patent/KR20030019623A/ko not_active Withdrawn
- 2001-07-26 CN CN2009102523811A patent/CN101732333B/zh not_active Expired - Fee Related
- 2001-07-26 JP JP2002501211A patent/JP5117660B2/ja not_active Expired - Lifetime
- 2001-07-26 DK DK01954360T patent/DK1308168T3/da active
- 2001-07-26 DE DE60134324T patent/DE60134324D1/de not_active Expired - Lifetime
- 2001-07-26 AT AT01954360T patent/ATE397458T1/de active
- 2001-07-26 ES ES01954360T patent/ES2307633T3/es not_active Expired - Lifetime
- 2001-07-26 WO PCT/JP2001/006467 patent/WO2002009754A1/ja active IP Right Grant
- 2001-07-26 EP EP20010954360 patent/EP1308168B1/en not_active Expired - Lifetime
- 2001-07-26 CA CA 2417255 patent/CA2417255C/en not_active Expired - Fee Related
- 2001-07-26 CN CN01816215A patent/CN100581585C/zh not_active Expired - Fee Related
2007
- 2007-06-11 US US11/761,264 patent/US7879327B2/en not_active Expired - Fee Related
2010
- 2010-12-23 US US12/978,275 patent/US9139658B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CN1466464A (zh)	2004-01-07
US20080031881A1 (en)	2008-02-07
US7449181B2 (en)	2008-11-11
DE60134324D1 (de)	2008-07-17
US9139658B2 (en)	2015-09-22
WO2002009754A1 (fr)	2002-02-07
US7879327B2 (en)	2011-02-01
EP1308168A1 (en)	2003-05-07
CA2417255C (en)	2011-08-02
JP5117660B2 (ja)	2013-01-16
US20030157097A1 (en)	2003-08-21
US20110104160A1 (en)	2011-05-05
AU2001276689A1 (en)	2002-02-13
CN101732333B (zh)	2012-08-15
CN100581585C (zh)	2010-01-20
ES2307633T3 (es)	2008-12-01
CA2417255A1 (en)	2003-01-24
TWI317285B (en)	2009-11-21
EP1308168A4 (en)	2004-09-01
ATE397458T1 (de)	2008-06-15
EP1308168B1 (en)	2008-06-04
CN101732333A (zh)	2010-06-16
KR20030019623A (ko)	2003-03-06

Publication	Publication Date	Title
DK1308168T3 (da)	2008-07-28	Nye lægemidler mod cancer
BR0311443A (pt)	2005-03-22	Método e dispositivo para controlar farmacocinética de droga
DE602004027936D1 (de)	2010-08-12	Tocopherolmodifizierte therapeutische arzneimittelverbindung
NO20053224D0 (no)	2005-07-01	Patient controlled drug administration device.
AR027355A1 (es)	2003-03-26	Acidos tiazolidincarboxilicos
CY1112473T1 (el)	2015-12-09	Μεθοδοι θεραπειας για καρκινους σχετιζομενους με β κυτταρα
DK0740650T3 (da)	2004-09-27	Codrugs som metode til styret transport af lægemiddel
ZA200405657B (en)	2005-08-29	Formulation & dosage form for the controlled delivery of therapeutic agents.
ITTO20001224A0 (it)	2000-12-29	Dispositivo portatile per infusione di farmaci.
UY27455A1 (es)	2003-04-30	Derivados n-(1,4,5,6-tetrahidro-ciclopentapirazol -3-il)- sustituidos. su obtención y uso como fármacos.
NO20032027L (no)	2003-07-04	Effektive antitumorbehandlinger
DE60001974D1 (de)	2003-05-08	Derivate von flavonen, xanthonen und kumarinen
EP1379508A4 (en)	2005-12-28	N- (ARYL) -2-ARYLETHESULFONAMIDES AND THEIR THERAPEUTIC APPLICATIONS
DE60102590D1 (de)	2004-05-06	Darreichungsformen zur behandlung von oralen mykosen
EP1453507A4 (en)	2005-06-08	SOLUBILIZED TOPOISOMERASE GIFT MEDIUM
ITTO991129A0 (it)	1999-12-21	Siringa per infusione di farmaci.
NO20031410L (no)	2003-03-27	Anvendelse av distamycinderivater for fremstilling av medikamenter
EP1208840A3 (en)	2003-05-21	Combination of fluorouracil and a methylol transfer agent for the treatment of tumor metastases and cancer
EE200200605A (et)	2004-04-15	Asendatud akrüloüüldistamütsiini derivaadi kasutamine ravimi valmistamiseks, mis on ette nähtud glutatiooni kõrge tasemega seotud kasvajate raviks
AR037543A1 (es)	2004-11-17	Metodo para la terapia del cancer y composicion farmaceutica
AR109456A2 (es)	2018-12-12	Uso de et743 para la preparación de un medicamento para el tratamiento de un paciente humano afectado por cáncer mediante terapia de combinación
RU2000102259A (ru)	2001-11-10	Способ лечения хламидийного конъюнктивита
DE60214412D1 (de)	2006-10-12	Simplifizierte sarcodictyn-derivate als anti-tumor-mittel
RU99118112A (ru)	2001-06-20	Способ лечения больных с невротическими расстройствами препаратом "миелопид"
AR033579A1 (es)	2003-12-26	Terapia antitumoral que comprende derivados de distamicina